Ligand Pharmaceuticals Incorporated (LGND) Q1 2023 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.7%

Ligand Pharmaceuticals reported a strong earnings per share figure, significantly exceeding expectations, which contributed to a 1.7% increase in stock price. The company did not disclose revenue figures or future guidance, leaving some uncertainty for investors. Overall, the positive EPS surprise indicates strong operational performance.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$2.28	N/A	+296.52%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management expressed satisfaction with the EPS results, highlighting their commitment to growth. However, they did not provide specific guidance for the upcoming quarters.

We are pleased with our EPS performance this quarter.

Our focus remains on strategic growth and innovation.

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.7%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Up 1.7%

Key numbers

Management commentary